Screener
Aclaris Therapeutics ACRS Single Reportable — Research And Development Expense Other
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept acrs:ResearchAndDevelopmentExpenseOther.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| (In thousands) | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Discovery | 1,972 | 749 | 3,411 | 1,417 |
| Total research and development project expense(1) | 13,632 | 7,003 | 24,109 | 14,160 |
| Personnel | 3,036 | 2,984 | 6,317 | 5,911 |
| Other research and development(2) | 1,398 | 1,462 | 3,297 | 2,962 |
| Total research and development | 18,066 | 11,449 | 33,723 | 23,033 |
| General and administrative(3) | 6,048 | 5,386 | 12,791 | 11,525 |
| Licensing | 1,235 | 1,335 | 2,628 | 2,345 |
| Revaluation of contingent consideration | 300 | 1,500 | 300 | 1,800 |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's single reportable — research and development expense other?
- Aclaris Therapeutics (ACRS) reported single reportable — research and development expense other of $1.4M in Q2 2026.
- How has Aclaris Therapeutics's single reportable — research and development expense other changed year-over-year?
- Aclaris Therapeutics's single reportable — research and development expense other decreased by 4.4% year-over-year, from $1.46M to $1.4M.
- What does single reportable — research and development expense other mean?
- Encompasses miscellaneous research and development costs not categorized as personnel charges, such as laboratory supplies, equipment maintenance, or third-party research services. This metric provides insight into the non-labor operational intensity of the segment's innovation efforts. It helps investors understand the overhead required to support scientific discovery.
Ask your AI about Aclaris Therapeutics's single reportable — research and development expense other.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude